EE05432B1 - Prroloprimidiinid kui valgukinaasi inhibiitorid - Google Patents

Prroloprimidiinid kui valgukinaasi inhibiitorid

Info

Publication number: EE05432B1
Authority: EE; Estonia
Prior art keywords: rrolop; rimidines; protein kinase; kinase inhibitors; inhibitors
Prior art date: 2001-06-23

Application number

EEP200400003A

Other languages

English (en)

Estonian (et)

Inventor

Joseph Cox Paul

Nadeem Majid Tahir

Amendola Shelley

Daniele Deprets Stephanie

Edlin Chris

Leslie Pedgrift Brian

Halley Frank

Edwards Michael

Baudoin Bernard

Mcfarlane Mclay Lain

John Aldous David

Original Assignee

Aventis Pharmaceuticals Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-06-23

Filing date

2002-06-21

Publication date

2011-06-15

2002-06-21 Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.

2004-02-16 Publication of EE200400003A publication Critical patent/EE200400003A/xx

2011-06-15 Publication of EE05432B1 publication Critical patent/EE05432B1/xx

Links

229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Dermatology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Otolaryngology (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

EEP200400003A 2001-06-23 2002-06-21 Prroloprimidiinid kui valgukinaasi inhibiitorid EE05432B1 (et)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB0115393.1A GB0115393D0 (en)	2001-06-23	2001-06-23	Chemical compounds
US30167801P	2001-06-28	2001-06-28
PCT/GB2002/002835 WO2003000695A1 (en)	2001-06-23	2002-06-21	Pyrrolopyrimidines as protein kinase inhibitors

Publications (2)

Publication Number	Publication Date
EE200400003A EE200400003A (et)	2004-02-16
EE05432B1 true EE05432B1 (et)	2011-06-15

Family

ID=9917225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EEP200400003A EE05432B1 (et)	2001-06-23	2002-06-21	Prroloprimidiinid kui valgukinaasi inhibiitorid

Country Status (22)

Country	Link
EP (1)	EP1404676A1 (es)
JP (1)	JP4344607B2 (es)
CN (1)	CN1294135C (es)
AU (1)	AU2002314325B8 (es)
BR (1)	BR0210652A (es)
CA (1)	CA2451932C (es)
CZ (1)	CZ20033443A3 (es)
EA (1)	EA007415B1 (es)
EC (1)	ECSP034922A (es)
EE (1)	EE05432B1 (es)
GB (1)	GB0115393D0 (es)
HU (1)	HUP0400300A3 (es)
ME (1)	MEP19308A (es)
NZ (1)	NZ529766A (es)
OA (1)	OA12632A (es)
PL (1)	PL374096A1 (es)
RS (1)	RS51698B (es)
SK (1)	SK15882003A3 (es)
TN (1)	TNSN03144A1 (es)
TR (1)	TR200302242T2 (es)
UA (1)	UA76760C2 (es)
WO (1)	WO2003000695A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0202679D0 (en) *	2002-02-05	2002-03-20	Glaxo Group Ltd	Novel compounds
HRP20050089B1 (hr)	2002-07-29	2015-06-19	Rigel Pharmaceuticals	Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (en)	2003-07-30	2005-02-10	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
CA2546192C (en)	2003-11-17	2010-04-06	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
EP1689407A1 (en) *	2003-11-25	2006-08-16	Pfizer Products Inc.	Method of treatment of atherosclerosis
US20050250829A1 (en) *	2004-04-23	2005-11-10	Takeda San Diego, Inc.	Kinase inhibitors
WO2006023931A2 (en)	2004-08-18	2006-03-02	Takeda San Diego, Inc.	Kinase inhibitors
FR2876103B1 (fr)	2004-10-01	2008-02-22	Aventis Pharma Sa	Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1812439B2 (en)	2004-10-15	2017-12-06	Takeda Pharmaceutical Company Limited	Kinase inhibitors
FR2878849B1 (fr)	2004-12-06	2008-09-12	Aventis Pharma Sa	Indoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2008543855A (ja)	2005-06-13	2008-12-04	ライジェルファーマシューティカルズ，インコーポレイテッド	変形性骨疾患を処置するための方法および組成物
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
SG10202003901UA (en)	2005-12-13	2020-05-28	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
SG158147A1 (en)	2006-10-09	2010-01-29	Takeda Pharmaceutical	Kinase inhibitors
KR20150036210A (ko)	2007-06-13	2015-04-07	인사이트 코포레이션	야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
EP2247596A2 (en)	2008-01-11	2010-11-10	Natco Pharma Limited	Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
CN104592231A (zh)	2008-06-10	2015-05-06	Abbvie公司	新的三环化合物
SI2432472T1 (sl)	2009-05-22	2019-11-29	Incyte Holdings Corp	3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es)	2009-05-22	2011-07-06	Incyte Corp	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
WO2011018894A1 (en) *	2009-08-10	2011-02-17	Raqualia Pharma Inc.	Pyrrolopyrimidine derivatives as potassium channel modulators
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2485589A4 (en)	2009-09-04	2013-02-06	Biogen Idec Inc	HETEROARYL-BTK INHIBITORS
RU2711869C3 (ru)	2009-12-01	2022-02-02	Эббви Инк.	Имидазопирролопиразиновые производные, полезные для лечения заболеваний, вызванных аномальной активностью протеинкиназ Jak1, Jak3 или Syk
EP3354652B1 (en)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es)	2010-05-21	2013-02-27	Incyte Corp	Formulacion topica para un inhibidor de jak
PE20140146A1 (es)	2010-11-19	2014-02-06	Incyte Corp	Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103476776B (zh) *	2011-01-07	2016-09-28	北京赛林泰医药技术有限公司	作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN102093364B (zh) *	2011-01-07	2015-01-28	北京赛林泰医药技术有限公司	作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物
CN103797010B (zh)	2011-06-20	2016-02-24	因塞特控股公司	作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
JP6182593B2 (ja)	2012-04-20	2017-08-16	アドヴィーナスセラピューティクスリミテッド	置換ヘテロ二環化合物、組成物及び医薬並びにそれらの用途
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
KR101916443B1 (ko)	2012-07-26	2018-11-08	글락소 그룹 리미티드	Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
EP2892534B8 (en) *	2012-09-06	2021-09-15	Plexxikon Inc.	Compounds and methods for kinase modulation, and indications therefor
PH12020551186B1 (en)	2012-11-15	2024-03-20	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr)	2013-03-06	2022-02-28	Incyte Holdings Corp	Postupci i intermedijeri za dobijanje inhibitora jak
WO2014159999A1 (en)	2013-03-13	2014-10-02	Abbvie Inc.	Cdk9 kinase inhibitors
EP2970200A1 (en)	2013-03-13	2016-01-20	Abbvie Inc.	Pyridine cdk9 kinase inhibitors
WO2014151444A1 (en)	2013-03-14	2014-09-25	Abbvie Inc.	Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors
US9796708B2 (en)	2013-03-14	2017-10-24	Abbvie Inc.	Pyrrolo [2,3-B] pyridine CDK9 kinase inhibitors
AU2014244194A1 (en)	2013-03-14	2015-09-10	Abbvie Inc.	Pyrrolopyrimindine CDK9 kinase inhibitors
SMT202000315T1 (it)	2013-08-07	2020-07-08	Incyte Corp	Forme di dosaggio a rilascio prolungato per un inibitore di jak1
CN104804001B9 (zh) *	2014-01-24	2022-02-08	江苏柯菲平医药股份有限公司	4-取代吡咯并[2,3-d]嘧啶化合物及其用途
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US11524964B2 (en)	2015-10-16	2022-12-13	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en)	2015-10-16	2025-07-22	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11512092B2 (en)	2015-10-16	2022-11-29	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en)	2015-10-16	2023-10-03	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en)	2015-10-16	2022-06-21	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en)	2015-10-16	2020-02-04	Abbvie Inc.	Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
SG10201913990RA (en)	2015-10-16	2020-03-30	Abbvie Inc	PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
AU2018230500B2 (en)	2017-03-09	2024-03-07	Abbvie Inc.	Methods of treating Crohn's disease and ulcerative colitis
US11564922B2 (en)	2017-03-09	2023-01-31	Abbvie Inc.	Methods of treating crohn's disease and ulcerative colitis
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en)	2018-01-30	2020-08-28	Incyte Corp	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it)	2018-03-30	2024-09-16	Incyte Corp	Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
MX2021003904A (es)	2018-10-05	2021-10-26	Annapurna Bio Inc	Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor apj.
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1441497A (en) *	1996-01-23	1997-08-20	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
WO1998023613A1 (en) *	1996-11-27	1998-06-04	Pfizer Inc.	Fused bicyclic pyrimidine derivatives
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
SK286640B6 (sk) *	1998-06-19	2009-03-05	Pfizer Products Inc.	Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva
ES2253930T3 (es) *	1998-09-18	2006-06-01	ABBOTT GMBH & CO. KG	4-aminopirrolopirimidinas como inhibidores de quinasa.
DE60037345T2 (de) *	1999-12-10	2008-11-13	Pfizer Products Inc., Groton	Pyrrolo(2,3-d)pyrimidin-Verbindungen

2001
- 2001-06-23 GB GBGB0115393.1A patent/GB0115393D0/en not_active Ceased
2002
- 2002-06-21 ME MEP-193/08A patent/MEP19308A/xx unknown
- 2002-06-21 CZ CZ20033443A patent/CZ20033443A3/cs unknown
- 2002-06-21 RS YU99203A patent/RS51698B/sr unknown
- 2002-06-21 WO PCT/GB2002/002835 patent/WO2003000695A1/en not_active Ceased
- 2002-06-21 CA CA002451932A patent/CA2451932C/en not_active Expired - Fee Related
- 2002-06-21 TR TR2003/02242T patent/TR200302242T2/xx unknown
- 2002-06-21 BR BR0210652-3A patent/BR0210652A/pt not_active Application Discontinuation
- 2002-06-21 AU AU2002314325A patent/AU2002314325B8/en not_active Ceased
- 2002-06-21 JP JP2003507098A patent/JP4344607B2/ja not_active Expired - Fee Related
- 2002-06-21 TN TNPCT/GB2002/002835A patent/TNSN03144A1/en unknown
- 2002-06-21 NZ NZ529766A patent/NZ529766A/en not_active IP Right Cessation
- 2002-06-21 UA UA2004010502A patent/UA76760C2/uk unknown
- 2002-06-21 EP EP02740895A patent/EP1404676A1/en not_active Withdrawn
- 2002-06-21 PL PL02374096A patent/PL374096A1/xx not_active Application Discontinuation
- 2002-06-21 CN CNB028119320A patent/CN1294135C/zh not_active Expired - Fee Related
- 2002-06-21 OA OA1200300335A patent/OA12632A/en unknown
- 2002-06-21 EA EA200400073A patent/EA007415B1/ru not_active IP Right Cessation
- 2002-06-21 SK SK1588-2003A patent/SK15882003A3/sk not_active Application Discontinuation
- 2002-06-21 EE EEP200400003A patent/EE05432B1/xx not_active IP Right Cessation
- 2002-06-21 HU HU0400300A patent/HUP0400300A3/hu unknown
2003
- 2003-12-23 EC EC2003004922A patent/ECSP034922A/es unknown

Also Published As

Publication number	Publication date
TR200302242T2 (tr)	2004-12-21
CA2451932C (en)	2009-12-29
AU2002314325B2 (en)	2009-01-08
JP4344607B2 (ja)	2009-10-14
BR0210652A (pt)	2004-08-10
OA12632A (en)	2006-06-14
NZ529766A (en)	2008-11-28
WO2003000695A1 (en)	2003-01-03
SK15882003A3 (sk)	2004-07-07
EA200400073A1 (ru)	2004-08-26
UA76760C2 (uk)	2006-09-15
HUP0400300A3 (en)	2010-12-28
CN1294135C (zh)	2007-01-10
EA007415B1 (ru)	2006-10-27
EP1404676A1 (en)	2004-04-07
CZ20033443A3 (en)	2004-03-17
GB0115393D0 (en)	2001-08-15
EE200400003A (et)	2004-02-16
PL374096A1 (en)	2005-09-19
RS99203A (sr)	2006-12-15
HUP0400300A2 (en)	2007-08-28
ECSP034922A (es)	2004-04-28
TNSN03144A1 (en)	2005-12-23
WO2003000695A8 (en)	2004-03-11
CA2451932A1 (en)	2003-01-03
CN1518552A (zh)	2004-08-04
MEP19308A (en)	2010-06-10
JP2005508300A (ja)	2005-03-31
RS51698B (sr)	2011-10-31
AU2002314325B8 (en)	2009-01-29

Legal Events

Date	Code	Title	Description
2013-02-15	MM4A	Lapsed by not paying the annual fees	Effective date: 20120621

Publication	Publication Date	Title
EE05432B1 (et)	2011-06-15	Prroloprimidiinid kui valgukinaasi inhibiitorid
NO20041887L (no)	2004-05-07	Benzomidazoler anvendelige som proteinkinase-inhibitorer
DE60128709D1 (de)	2007-07-12	Triazol-verbindungen als protein-kinase-inhibitoren
DE60129794D1 (de)	2007-09-20	Pyrrol substituierte indolin-2-on protein kinase inhibitoren
IS6968A (is)	2003-09-26	Nýir týrósínkínasa tálmar
EE200200140A (et)	2003-04-15	Pteridinoonid kui kinaasi inhibiitorid
EE200300385A (et)	2004-02-16	3-(4-amidopürrool-2-üülmetülideen)-2-indolinooni derivaadid kui proteiini kinaasi inhibiitorid
DE60119776D1 (de)	2006-06-22	Pyrazolverbindungen als protein-kinase-inhibitoren
ATE505471T1 (de)	2011-04-15	Azaindol-kinaseinhibitoren
ID30460A (id)	2001-12-06	Inhibitor-inhibitor protein siklik tirosin kinase
DK1370553T3 (da)	2006-09-11	Rho-kinase-inhibitorer
DK1370552T3 (da)	2007-05-07	Rho-kinase-inhibitorer
EE200300384A (et)	2003-12-15	Kinasoliinid kui MMP-13 inhibiitorid
NO20035728L (no)	2004-02-23	Pyrrolopyrimidiner som proteinkinaseinhibitorer
DE60101323D1 (de)	2004-01-08	Tricyclische proteinkinasehemmer
IL151779A0 (en)	2003-04-10	Protein tyrosine kinase inhibitors
IL145329A0 (en)	2002-06-30	Protein tyrosine kinase inhibitors
DK1317448T4 (da)	2011-05-30	Pyrazolforbindelser anvendelige som proteinkinaseinhibitorer

EE05432B1 - Prroloprimidiinid kui valgukinaasi inhibiitorid - Google Patents